Profitability
Weight: 20%
F
0
- 5yr Avg ROIC -33.2%
- Operating Margin Trend -2646.40 pp/yr
CDTX
Cidara Therapeutics, Inc.
AlphaQuality composite grade, weighted for stable earnings power businesses.
⚠ 5 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a stable earnings power business.
Grade overrides the 22.4 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
F
0
- 5yr Avg ROE -41.8%
- 5yr Share-Count CAGR 32.2%
Growth Quality
Weight: 15%
F
15
- 5yr Revenue CAGR -43.0%
- 5yr EPS CAGR 0.0%
- Revenue-Growth Years (5) 2/5
Cash Generation
Weight: 15%
F
0
- 5yr FCF Margin -2900.4%
- 5yr FCF/NI Conversion 0.00x
Balance Sheet
Weight: 20%
C
55
- Net Debt / EBITDA 10.00x
- Interest Coverage (EBIT/Int) 30.00x
- Altman Z-Score 32.58
Stability
Weight: 15%
C+
62
- EPS Volatility (σ/μ) 0.00
- Piotroski F-Score 2
- Negative-Revenue Years (5) 3/5
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.0 of 4 gurus held; 4 full exits.
- Holders
- 0 -4
- Avg Δ position
- —
- New buys
- 0
- Full exits
- 4
- Cooperman sold -100%
- Soros sold -100%
- Druckenmiller sold -100%